Roman, Antonio; Barberà, Joan A. Barber; Escribano, Pilar - In: Applied Health Economics and Health Policy 10 (2012) 3, pp. 175-188
profile and economic aspects. Abstract: Objective:Objective: This study provides a cost-effectiveness and cost … treprostinil (2.69 LYG and 1.73 QALY). Incremental cost-effectiveness ratios (ICER) and cost-utility ratios (ICUR) of epoprostenol … dominant strategy in 15% of the simulations, but it was not a cost-effective option in 83% of the cases. When compared with …